chrisvoncsefalvay/vaers-outcomes huggingface dataset:
18-20 hours after receiving the injection he noticed that "his heart would beat "hard"/heart beating fast; about 18 to 20 hours later the next morning he was experiencing something like a palpitation; arm hurt that night and the next morning/sore arm of course; This is a spontaneous report from a contactable consumer (patients wife).   A 76-years-old male patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE; Lot Number: EL9261) , via an unspecified route of administration on 21Jan2021 at 14:30 (at the age of 76-years-old) in the left arm  as SINGLE DOSE for covid-19 vaccination. Medical history included cardiac murmur and Type 2 Diabetic. There were no concomitant medications.  On 21Jan2021 the patient experienced arm hurt that night and the next morning/sore arm, and On 22Jan2021, 18-20 hours after receiving the injection he noticed that 'his heart would beat hard' /heart beating fast/he was experiencing something like a palpitation. Report described that it is like when you get scared. This Happens 2-3 times a day and it is not constant. The patient  went to his primary care physician on Friday for a 'routinely scheduled annual check up' and  mentioned this to her at his appointment. His provider encouraged him to call Pfizer and report these symptoms. His doctor is going to continue to follow up with him and if the problem persists do further tests. Lab data included heart rate on 22Jan2021 18-20 hours after injection his heart would beat hard /would be fast/something like a palpitation. The clinical outcome of heart beating fast was not recovered while palpitations and arm pain were unknown.
This spontaneous report was received from an unspecified reporter who ported an article in a web site concerning to a 193 students of an unknown age and gender. The patients's concurrent conditions, medical history, historical drugs and concomitant medication were not reported.  On unknown dates, the patients were vaccinated with two doses of M-M-R II (dose, route, lot number and expiration date were not reported) for prophylaxis. On unknown dates (August), the patients got mumps. It was reported that "in spite of two vaccines as a school requirement, the students got sick anyway" A reporter stated "a fact that we had mumps showing up in highly immunized populations likely reflects something about the effectiveness of the vaccine".  At the time of the report, the outcome of mumps and vaccination failure was not reported. The causal relationship between the events and M-M-R II was not reported. This is one of the several reports received from the same reporter. Additional information is not expected as there is not contact details of the reporter.; Sender's Comments: US-009507513-1701USA005463:         Original Case : 1701USA005463 US-009507513-1701USA006590:
This case was reported by a pharmacist and described the occurrence of bruise injection site in a subject of unspecified age and gender who was vaccinated with FLUARIX. On 11 October 2013 the subject received a dose of FLUARIX (.5 ml, subcutaneous, unknown arm) and experienced inappropriate route of vaccination. FLUARIX should be administered as an intramuscular injection and not injected subcutaneously. In October 2012, less than a week since vaccination with FLUARIX, the subject experienced bruise injection site, and swelling injection site. The reporter was not able to provide specific details as to the onset of the adverse events. At the time of reporting the outcome of the events was unknown. The pharmacist reported four cases with inappropriate route of vaccination, bruise injection site and swelling injection site. The pharmacist did not know if there were more than four employees that were given FLUARIX by subcutaneous route versus intramuscular route. See cases A0998038A, A0998039A, and A0998040A.
I am currently breastfeeding my 4 month old son. He started pooping blood 4 hours after my 1st dose of the vaccine.  His next 3 stools were blood streaked and then returned to normal 3/10/2020
Information has been received from a registered pharmacist (R.Ph.) and a physician concerning a 7 months old female patient who on 20-AUG-2010 was vaccinated with her first dose of ROTATEQ (lot number 668401/0510Z; expiration date 29-MAR-2012). Concomitant therapy received the same day, included a second dose of HAVRIX (lot number AHBVB789BA), the first dose of PENTACEL (lot number C3659AA) and the first dose of PREVNAR 13 (lot number E79531). The physician stated that the patient had streaks of blood in her stool on approximately 20-AUG-2010 "within two days" after receiving ROTATEQ and the concomitants vaccinations. No hospitalization or treatment was needed and the patient recovered. On 20-OCT-2010, the patient received the second dose of ROTATEQ (lot number 668266/0521Z; expiration date 09-APR-2012). Concomitant therapy received the same day, included a second dose of PENTACEL (lot number C3635AA) and the second dose of PREVNAR 13 (lot number E87934). The patient had streaks of blood in her stool on approximately 20-OCT-2010 "within two days" after receiving ROTATEQ and the concomitants vaccinations. No hospitalization or treatment was needed and the patient recovered. The physician stated that she was "leaning towards the patient not receiving the third dose of ROTATEQ". Upon internal review, bloody stools was considered to be an other important medical event. Additional information is not expected.
few days over 6 months for 2nd dose; This case was reported by a consumer via interactive digital media and described the occurrence of incomplete course of vaccination in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   Previously administered products included Shingles vaccine (1st dose of shingles vaccine received on unknown date).   On an unknown date, the patient did not receive the 2nd dose of Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the incomplete course of vaccination was unknown.   Additional Information: GSK Receipt Date: 10-JAN-2023 Reporter's Comments: This case was reported by a patient via (Shingrix GSK) interactive digital media. The reporter asked that if he/she was a few days over six months for getting his/her second dose of Shingles vaccine, could he/she still got it. Additional Supportive Information: Till the time of reporting, the patient did not receive the 2nd dose of Shingles vaccine, which led to incomplete course of vaccination. The follow up would not possible as no contact details were available.
The afternoon of the vaccine, patient's whole body ached. She felt weak and fell over getting up. No syncope. Temp 100-101. Side of body where she got vaccine was "twitching" per mother. She was dizzy. Today, day after vaccine, side of body where she got vaccine is achy.
Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from product quality group. The reporter is the patient.  A female patient in her 50's (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 20Nov2022 at 12:00 as dose number unknown (booster), single (Lot number: GH9703) at the age of 58 years, in left arm for covid-19 immunisation; BNT162b2 (BNT162B2), on 13Dec2021 as dose number unknown, single (Lot number: 320308D), in left arm for covid-19 immunisation. The patient's relevant medical history included: "High Blood pressure (HBP)" (unspecified if ongoing), notes: Controlled HBP (High blood pressure) with Lisinopril 10mg. Concomitant medication(s) included: MUCINEX DM, start date: 01Dec2022, stop date: 13Dec2022; LISINOPRIL taken for hypertension. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset Dec2022, outcome "unknown" and all described as "Treatment of COVID-19". Therapeutic measures were taken as a result of drug ineffective, covid-19: Paxlovid.
3-4 days after vaccine, developed fever and flu-like symptoms, then developed erythematous maculopapular rash.  Had a few vesicles and pustules, no cellulitis
Pt reported to office 3 days after vaccines given. Approx 4 X 6 area of redness, warmth, and tenderness at site of DTaP and IPV.
This spontaneous report was received from a Registered Nurse referring to a patient of unknown age and gender. Information about the patient's medical history and concurrent conditions was not provided. On 17-FEB-2016, the patient was vaccinated with an improperly stored (Temperature: 32F - Time frame: 5 minutes) dose of VAQTA (lot # L023232 and expiration date: 25-FEB-2017, administration route was not provided). NO concomitant therapies were reported. No adverse effects were reported. This is one of several reports from the same reporter. Additional information has been requested.
Awoke with tender, red, swollen left arm at area where injcetion was given.  Limited range of motion.
home test yesterday was positive for Covid 19; home test yesterday was positive for Covid 19; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from product quality group. The reporter is the patient.  A 46-year-old female patient received BNT162b2 (BNT162B2), on 26Jan2021 as dose 1, single (Lot number: EN5318, Expiration Date: 31May2021), on 16Feb2021 as dose 2, single (Lot number: EN5318, Expiration Date: 31May2021) and on 08Oct2021 as dose 3 (booster), single (Lot number: EW0217) at the age of 46 years, in left arm for covid-19 immunisation. The patient had no relevant medical history. The patient's concomitant medications were not reported. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset 19Jun2022, outcome "unknown" and all described as "home test yesterday was positive for Covid 19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (19Jun2022) Positive, notes: Result: positive; Unit: Not Provided; (18Jun2022) unknown results, notes: Result: unknown; Unit: Not Provided.  Clinical course: AE(s) did not require a visit to: Emergency Room or Physician Office. Prior Vaccinations within 4 weeks was reported as none. Patient's Medical History and Family Medical History Relevant to AE was none.
Began chills and low grade fever (100 degrees) around 1:30 p.m. the day following receipt of my Pfizer booster that continued through the night.  All symptoms were gone the following day.  ***Had no adverse reaction to my First & Second Pfizer vaccination.  That's what was so unusual about this reaction.
Spotting has occured daily since the day after vaccine was administered on 5/14/21.  Menstrual cycle typically regular and was expected to begin on 5/29/21.
approx 30min p/vax pt was noted to be choking on thick secretions in mouth lasted 15-20min assoc w/diff breathing secretions thick foaming;
Information has been received from a physician concerning a 17 year old female with no history of varicella virus vaccine live vaccination and an unknown history of varicella, who on 11-SEP-2006 was vaccinated intramuscularly with a 0.5 ml dose of HPV rL1 6 11 16 18 VLP vaccine (yeast). There was no concomitant medication. The physician reported that on 12-SEP-2006 "the next day, the patient developed a low grade fever and a vesicular rash on her neck and shoulders of about 15-20 lesions." The patient was treated with acetaminophen (TYLENOL). All of her symptoms resolved within 3-4 days (approximately 15-SEP-2006). Additional information has been requested.
Vaccine administered 09:30, within 30 minutes, at 10:00, left arm became pruritic, red and warm to touch. Also, chest was red, face flushed, sweating, and felt clammy. Alerted co-worker who informed employee health RN. She observed the same symptoms, applied a cold compress for my arm and gave me a 25 mg BENADRYL capsule. Around 12:30 (10/10/17), became flushed and was sweating again. Co-worker called Employee Health RN again. My supervisor administered another cold compress to me. They recommended I call my PCP as they did not want to give me another BENADRYL without her consent. PCP instructed to have my work administer another 25 mg BENADRYL immediately. The PCP instructed to give another 25 mg BENADRYL before bedtime. There were no more reactions to the vaccine after the 12:30 PM flareup.
ONSET OF FEVER AND SORE THROAT FOLLOWING DAY. ON SATURDAY, AUGUST 11, PATIENT HAD TROUBLE WALKING, SLURRED SPEACH AND VISION PROBLEMS. 30 MINUTES LATER, AT HOSPITAL, HE HAD DIAREAH AND WAS VOMITTING. SUBSEQUENTLY WENT INTO COMA AND BECAME VERY IRRITABLE WHEN TOUCHED. (TOOK SEVERAL OF US TO HOLD HIM DOWN FOR THIRD IV). ADMITTED TO PEDIATRIC ICU AND, AFTER CT SCAN, SPINAL AND SOMETHING ELSE WAS PUT ON ANTIVIRAL MEDICATION AS A PRECAUTION. HE WAS HEAVILY SEDATED FOR SPINAL. WHEN HE AWOKE AT 3:00 A.M. ON SUNDAY AUGUST 12, HE HAD DOUBLE VISION, HEADACHES- HOWEVER HE WAS SPEAKING WITHOUT SLURRING.HE WAS HOSPITALIZED UNTIL AUGUST 14 WHEN ALL TESTS CAME BACK NEGATIVE AND HE COULD COME OFF ANTIVIRAL MEDS. HIS EEG SHOWED ABNORMALITIES AND WE ARE TO GO FOR FOLLOW UP. 10/22/07-records received for DOS 8/11-8/15/07- DC DX:Hypnatremia, delirium, neurological deficits. Seen in ER for hyponatremia, delirium, neruo deficits, blurred vision, slurred speech, unsteady gait, low grade fever.  Recent travel.
Patient reported developing large rash at inject site after administration of the flu vaccine. 4 days had passed and rash has not cleared.
10-3-11 - Flu vaccine give (L) deltoid. 10-4-11 - Lump at injection site, numbness (L) arm to 4-5th fingers, nausea & vomiting & diarrhea x 2 days. Lost 2 work days.
Patient received 0.5mL of Moderna instead of 0.25 mL of Moderna Booster dose. Checked in with patient 24 hours after incident, and patient states he is feeling well, no other side effects besides slight arm soreness.
Systemic: Fainting / Unresponsive-Medium, Systemic: Nausea-Mild, Additional Details: Fainted, but came to within approx 1 min. Had upset stomach afterward. Remained in the pharmacy for approx 30 minutes after. Was able to walk out of pharmacy. Called pt next day and pt stated she was ok, her stomach was still a litle upset
Uncontrollable crying for seven hours followed jerking episode off and on for the next day.
VARIVAX was administered to patient while it had a temperature excursion; No additional AE; This spontaneous report was received from a nurse referring to a patient of unknown age and gender. The patient's historical medications, medical history, concurrent conditions and concomitant medications were not reported.      On an unknown date, the patient was vaccinated with an improperly stored dose of varicella virus vaccine live (oka/merck)(VARIVAX) dose 1, lot number W025274, expiration date 10-AUG-2024 (route of administration not reported) for prophylaxis (product storage error). No adverse event was reported.  The vaccines underwent a temperature excursion of 24.4 degrees Fahrenheit for 5 hours and 51 minutes. No previous excursions were detected.
No adverse rxn the day the injection was given. Fatigue the day after the injection was administered. Localized reaction that is swollen, warm, and tingles just below the injection site on the left deltoid. Cool compresses-swelling and hydrocortisone cream-redness.
fatigue, muscle aches, headache (I ordinarily never have headache) I had all day after about 11 am the day after the vaccination.  I awoke the following day to have the muscle aches reduced and the headache resolved, but the fatigue persists, and I have repetitively fallen asleep unintentionally.  It just appears to be letting up at about noon the second day after the vaccination.
pt recvd vax 7oct &  that pm had 3 brief generalized sz lasting 10-15 seconds w/ stiffening of all extremities; eye rolling & tongue thrusting; pe nl; cbc, lytes, bun, glucose, ca, mg, po4 nl; eeg pending;
Information has been received concerning a 68 year old female with rheumatoid arthritis, osteoporosis and pain who on 11/25/2005 was vaccinated (route unknown) with a dose of pneumococcal 23v polysaccharide vaccine (lot # unknown) and a jab of influenza virus vaccine unspecified. Concomitant therapy included diclofenac, leflunomide, tramadol HC1 (Tramadolor), cholecaloiferol, risedronate sodium (Actonel) and etanercept Enbrel. It was reported that a patient was a participant in a study. In the evening of 11/25/2005 the patient also had a dose of etanercept Enbrel. Approximately three months post initiation of etanercept Enbrel therapy and one day after Saturday 11/26/2005 receiving the Pneumococcal 23v polysaccharide vaccine, the patient started feeling ill (malaise), pain in joints (knees, elbows, all over body, arthralgia), and wasn't able to move (movement disorder). On 11/27/2005, the patient called the ambulance and was accepted as an inpatient on 11/28/2005 (2 days later) for an unknown period of time. Therapy with etanercept Enbrel was discontinued. The patient was diagnosed with polyarticular septic arthritis. Treatment included intravenous antibiotics unspecified. It was reported that the patient was re admitted to the hospital approximately one month later, additional details were not provided. It was reported that the septic arthritis was considered severe and it persisted. The reporter suspected the event was related to therapy with etanercept Enbrel and Pneumococcal 23v polysaccharide vaccine was identified as co suspect. The temporal relationship between the onset of the event and the administration of therapy suggests that a causal relationship is possible, however, causality is confounded by the concurrent use of diclofenac, leflunomide, tramadol HCL Tramadolor, and Pneumococcal 23v polysaccharide vaccine. Additional information is not expected.
tested positive for Covid-19; tested positive for Covid-19; She was advised by a physician that they will administer the second dose after 90 days; She was advised by a physician that they will administer the second dose after 90 days; This is a spontaneous report from a contactable consumer (patient) from the Pfizer-sponsored program. A female patient of unspecified age received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection), via an unspecified route of administration on 19Mar2021 (Batch/Lot number: not reported) as a single dose for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. The patient said that, after her first dose, she started getting sick and tested positive for COVID-19 on 08Apr2021. She was advised by a physician that they will administer the second dose after 90 days. The patient underwent lab tests and procedures which included SARS-CoV-2 test: positive on 08Apr2021. The outcome of the events was unknown.   Information on the batch/lot number has been requested.
Patient stated she experienced right neck pain and right shoulder pain and low grip strength with her right hand, beginning the weekend after the vaccination was given (vaccination given Thursday, Oct 12). She states she rested tried Acetaminophen and ALEVE / MOTRIN and felt a little better the week after the symptoms began but pain never resolved. She states she called her primary doctor and they referred her to the Emergency Room, where the doctor diagnosed what may be a bone cyst and prescribed her a steroid dose pack and ibuprofen 800 mg.
LOT OF BLOOD CLOTS RECUR; This spontaneous report received from a consumer concerned multiple (unspecified number) patients of an unspecified age, sex, race and ethnicity.   The patient's weight, height, and medical history were not reported. The patients received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, batch number and expiry date were not reported) dose, start therapy date were not reported, 1 total administered for covid-19 prophylaxis. The batch number was not reported and has been requested. No concomitant medications were reported.  On an unspecified date, the patients experienced lot of blood clots recur from one shot Janssen vaccine. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of lot of blood clots recur was not reported. This report was serious (Other Medically Important Condition).; Sender's Comments: V0: 20230606535- lot of blood clots recur. Insufficient information is available to make a causality assessment. Therefore, this event is considered unclassifiable.
Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 'vaccine administration date; Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 'vaccine administration date; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 'vaccine administration date) and PRODUCT STORAGE ERROR (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 'vaccine administration date) in a 51-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 066H21A) for COVID-19 vaccination.     No Medical History information was reported.    On 18-Mar-2022 at 4:07 PM, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On 18-Mar-2022 at 4:07 PM,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced EXPIRED PRODUCT ADMINISTERED (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 'vaccine administration date). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 'vaccine administration date). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 'vaccine administration date) and PRODUCT STORAGE ERROR (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 'vaccine administration date) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant product reported by reporter. Vaccine went into 2 to 8 degree Celsius in thaw state on or about 24 Dec 2021. No treatment medication reported by reporter.   This case was linked to MOD-2022-542869 (Patient Link).
Pt. states that after receiving the 3rd Booster of Moderna 11/18/2021, started experiencing symptoms 11/19/2021 of fever, chills, body aches, joint pain, nerve pain, headache, pallet blisters, dizziness, nausea, rash at the injection site, and dry cough. Symptoms are subsiding, Primary communications recommendation of Reporting to VAERS.
15 year old inadvertently was administered Moderna 0.50 mL as her first dose.
Day following vaccine, had extreme fatigue, headache, low grade fever, injection site redness  and swelling. All symptoms subsided after the first 48 hours with the exception of the injection site redness that lasted for 5 days along with itching at the site. The redness is now gone but itching at the site still remains at the injection site as of today-day 10. I consider the itching to be a minor side effect, and not severe enough to prevent me from getting the 2nd vaccination.
Took the moderna 1st test and within two hours of the vaccine, between the forefinger of my left hand and the thumb began to swell, tighten.  I observed it, it appeared to be a large clot, it stiffened almost paralyzing the area between these two fingers, it hurt, and then as suddenly as it came it left.  No further on the first vaccine.  On the second vaccine in the same hand, a day after the shot, my left hand swelled from the wrist to the fingers but especially in the area of the back of the hand. it nearly paralyzed moment in the hand, for at least two days.  it hurt extemely when I would attempt to move the hand back at the wrist, to move the hand in any way.  I took two motrins on the second day and it went away as suddenly as it began.  I have not had any other problem to date